HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Review: aggressive LDL lowering outweighs theoretical risks, yet few reach <55 mg/dL

Gokhan Can · Oct 28, 2025 · ♥ 13 reactions · 5 comments · original Facebook post
LDL, ApoB & lipid panelPCSK9, ezetimibe & newer drugsGuidelines, policy & public health
AI summary & key facts

Summarises a July 2025 review: guidelines now target LDL-C <55 mg/dL (<40 after a recurrent event), PCSK9 inhibitors add 59-62% LDL reduction, and evidence (FOURIER, CTT meta-analysis, PCSK9 genetics) supports benefit to very low levels. It says safety concerns such as hemorrhagic stroke, cognitive decline (EBBINGHAUS) and hormone disruption are unsupported, while fewer than one in four high-risk patients reach target.

Pushing the limits of LDL cholesterol

July 2025

This review argues that the cardiovascular benefits of aggressively lowering LDL cholesterol (LDL-C) significantly outweigh minimal, largely theoretical risks. The authors trace the evolution of guidelines, which now recommend stringent targets like <55 mg/dL for very high-risk patients (ACC/ESC) and even <40 mg/dL after a recurrent event (ESC). These goals are achievable with newer therapies like PCSK9 inhibitors, which provide a 59-62% LDL-C reduction on top of statins. Clinical trial evidence is robust: the FOURIER trial demonstrated a 15% reduction in primary cardiovascular endpoints by lowering LDL-C to a median of 30 mg/dL, while a major meta-analysis confirmed a 21% relative risk reduction for every 38.7 mg/dL (1 mmol/L) drop, with benefits extending to levels as low as 21 mg/dL. Genetic studies further support this, linking certain PCSK9 mutations to an 88% reduction in coronary heart disease. The review concludes that concerns about hemorrhagic stroke (NNH 3333), cognitive decline (refuted by the EBBINGHAUS study), or hormone disruption are not supported by large-scale data, yet a significant treatment gap remains, as fewer than one in four high-risk ASCVD patients currently achieve the <55 mg/dL target.

Paper · Trends in Cardiovascular Medicine · 2025Pushing the limits of LDL cholesterol: Emerging paradigms in cardiovascular risk reductionsciencedirect.com

Research cited

#cholesterol#cardiovascular#pcsk9#heartdisease#evolution#guidelines#statins#genetics
← newer: BMJ trial: stem cells after heart attack lowered heart failuolder: Stiff arteries linked to greater brain nerve fiber injury in →